Candel Therapeutics Inc
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Candel Therapeutics stock, expecting its value to rise significantly.
Financial Health
Candel Therapeutics shows strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial Catalysts Ahead
Upcoming clinical readouts can move the stock significantly; however, results can be binary and outcomes are uncertain.
Immunotherapy Approach
Oncolytic viruses aim to trigger immune responses against tumours — a promising scientific area, though clinical proof is essential.
Partnerships & Funding
Collaborations or capital raises can accelerate development but may dilute existing shareholders; monitor cash runway closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
